MAP2K7 and melanoma: A study analyzing biopsies from 16 patients with B-RAF-mutant melanoma treated with either Trametinib (a MEK inhibitor) or Dabrafenib/Vemurafenib (B-RAF inhibitors) found that six post-treatment samples exhibited a significant increase in EGFR expression, as determined by immunohistochemistry (IHC) [26].